For patients with advanced or metastatic kidney cancer, the long-term effectiveness of double immunotherapy is confirmed. Eight years later, in fact, the first line of treatment with nivolumab plus ipilimumab continues to demonstrate a greater survival benefit compared to sunitinib. The latest data from the CheckMate -214 study, made known during an oral presentation at the Genitourinary Cancers Symposium 2024 at Asco (25-27 January), show a 28% reduction in mortality, regardless of the risk group: everyone had maintained longer survival and longer-lasting response benefits compared to those treated with sunitinib.
by Tiziana Moriconi
New long-term survival data
Among patients at intermediate and unfavorable risk (nearly 850), those treated with the combination (425) showed improvements in terms of overall survival, progression-free survival, overall response rate and duration of response. Specifically, the median overall survival was 46.7 months compared to 26 months with sunitinib, and the 90-month rates were 32.9% and 22.0%, respectively. If we consider all the more than one thousand patients included in the study (and not just those at intermediate or unfavorable risk), the median long-term overall survival rises to 52.7 months compared to 37.8.
by Tiziana Moriconi
The longest follow up
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, twice as common in men than in women. At diagnosis, approximately 30% of patients have already advanced or metastatic disease. For Nizar Tannir, of the MD Anderson Cancer Center and professor in the Department of Genitourinary Medical Oncology at the University of Texas, the new data indicate that “this dual immunotherapy combination has the potential to help patients achieve positive long-term outcomes, regardless of risk”. This is the longest observation (follow up) period ever reported for a Phase 3 study for combination therapy with immunotherapeutics in advanced renal cell carcinoma, and “it is surprising to observe that, after eight years in, the combination of nivolumab and ipilimumab continues to demonstrate longer survival and durable responses.”
by Dario Rubino
Another important data concerns the safety profile of the association, which was manageable using consolidated treatment algorithms, without new safety signals. “These extensive results are further evidence to the scientific community of the potential we have long recognized for immunotherapy to transform treatment paradigms in oncology,” concludes Dana Walker, vice president, global program lead, gastrointestinal and genitourinary cancers at Bristol Myers Squibb – We are proud to find that the eight-year results indicate sustained overall survival with this front-line dual immunotherapy approach and reinforce its role as the current standard of care in this setting.”